ATE483979T1 - Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa - Google Patents

Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa

Info

Publication number
ATE483979T1
ATE483979T1 AT05770407T AT05770407T ATE483979T1 AT E483979 T1 ATE483979 T1 AT E483979T1 AT 05770407 T AT05770407 T AT 05770407T AT 05770407 T AT05770407 T AT 05770407T AT E483979 T1 ATE483979 T1 AT E483979T1
Authority
AT
Austria
Prior art keywords
cancer
anln
rhoa
small cell
cell lung
Prior art date
Application number
AT05770407T
Other languages
German (de)
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE483979T1 publication Critical patent/ATE483979T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05770407T 2004-08-10 2005-08-09 Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa ATE483979T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (1)

Publication Number Publication Date
ATE483979T1 true ATE483979T1 (de) 2010-10-15

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770407T ATE483979T1 (de) 2004-08-10 2005-08-09 Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa

Country Status (6)

Country Link
US (1) US20090297500A1 (https=)
EP (1) EP1787122B1 (https=)
JP (1) JP4874234B2 (https=)
AT (1) ATE483979T1 (https=)
DE (1) DE602005024021D1 (https=)
WO (1) WO2006016697A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
JP2010523081A (ja) * 2007-03-30 2010-07-15 オンコセラピー・サイエンス株式会社 Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP6127972B2 (ja) 2011-09-09 2017-05-17 コニカミノルタ株式会社 組織染色方法
CA3064363C (en) * 2011-10-24 2022-05-17 Somalogic, Inc. Non-small cell lung cancer biomarkers and uses thereof
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES

Also Published As

Publication number Publication date
EP1787122A1 (en) 2007-05-23
DE602005024021D1 (de) 2010-11-18
EP1787122B1 (en) 2010-10-06
US20090297500A1 (en) 2009-12-03
JP4874234B2 (ja) 2012-02-15
WO2006016697A1 (en) 2006-02-16
JP2008510126A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
ATE483979T1 (de) Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
IL258880A (en) Diarylhydantoin compounds
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
WO2009049214A3 (en) Inhibition and treatment of prostate cancer metastasis
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2020239895A3 (en) Detection of colorectal cancer
WO2014144657A3 (en) Compositions and methods for cancer prognosis
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
BRPI0403169A (pt) Prognósticos de câncer colorretal
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
DE602006005084D1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
You et al. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma
MX2008016269A (es) Fermentacion y purificacion de cromoproteinas actinomadura y especies relacionadas.
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
TW200716132A (en) Novel chemical compounds
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
WO2023004342A3 (en) Methods for identifying adar1 inhibitors, and compositions and methods of use in treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties